Chondroplasty Global Market Report 2024

The chondroplasty market size has grown strongly in recent years. It will grow from $12.92 billion in 2023 to $13.77 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to an increase in sports-related injuries, a preference among patients for non-total joint replacement, advances in postoperative care, enhanced training and expertise among healthcare providers, and a rising incidence of joint disorders.

The chondroplasty market size is expected to see strong growth in the next few years. It will grow to $17.29 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the integration of regenerative medicine, a focus on outpatient procedures, the introduction of novel biomaterials, the rise in musculoskeletal disorders, and the expansion of the geriatric population. Major trends in the forecast period include technological integration in rehabilitation, the adoption of arthroscopic techniques, advancements in cartilage repair and regeneration, innovations in surgical tools, and the integration of navigation systems.

The anticipated surge in joint-related disorders stands as a catalyst propelling the expansion of the chondroplasty market in the foreseeable future. These disorders encompass a range of health issues affecting joint functionality, often stemming from excessive joint use or abrupt injuries, such as accidents or sports-related incidents. Chondroplasty serves as a treatment for these joint-related disorders by addressing damaged cartilage within a joint. Recent data published by The Lancet in August 2023 highlighted a rise in the incidence of gout, an inflammatory arthritis impacting joints, in the UK. The diagnoses increased from 1.40 per 1,000 adults in March 2021 to 1.44 per 1,000 adults in March 2022. Furthermore, projections from the Centers for Disease Control and Prevention (CDC) in June 2023 estimate that by 2040, approximately 78.4 million (25.9%) US adults aged 18 years or older may receive doctor-diagnosed arthritis (BRFSS). Hence, the escalating prevalence of joint-related disorders is a driving force behind the chondroplasty market's growth trajectory.

The upswing in knee surgeries is poised to fuel the advancement of the chondroplasty market in the forthcoming period. Knee surgery denotes a surgical intervention targeting the knee joint to address a spectrum of conditions, injuries, or disorders impacting knee functionality. Chondroplasty, a surgical procedure focused on repairing and reshaping damaged cartilage within a joint, finds particular application in knee-related treatments. Notably, data from the National Library of Medicine revealed a substantial 18.3% increase in total hip and knee operations performed at over 1150 facilities in 2022 compared to 2020, totaling 2.4 million procedures. Moreover, projections from the same source in January 2023 indicate a projected surge of 139% in total knee arthroplasty (TKA) by 2040 and a striking 469% surge by 2060. As knee surgeries increase, the demand for chondroplasty is correspondingly boosted, fostering the growth dynamics of the chondroplasty market.

The prospective growth of the chondroplasty market has been hindered by limited reimbursement coverage for chondroplasty procedures. The existing reimbursement policies often impose restrictions on the frequency of chondroplasty treatments a patient can receive, posing challenges, particularly for individuals with recurring or extensive cartilage damage necessitating multiple procedures. Moreover, despite partial coverage, patients often face substantial out-of-pocket expenses, including deductibles, copayments, and coinsurance. These financial burdens may dissuade individuals, especially those facing financial constraints, from pursuing chondroplasty. An article published by the National Library of Medicine in December 2022 reported a concerning trend, a decrease in the average reimbursement rate per CPT code for hip arthroscopy procedures. In 2022, the rate dropped to $899.21, reflecting a notable decrease of $242.24 (21.1%) compared to the inflation-adjusted rate of $1,141.45 in 2011. This limited reimbursement coverage poses a significant obstacle to the expansion of the chondroplasty market.

Key players within the chondroplasty market are actively engaged in developing innovative technologies, such as articular cartilage segmentation tools, to enhance customer service offerings. An articular cartilage segmentation tool is a software application designed to automatically or semi-automatically segment articular cartilage from magnetic resonance imaging (MRI) scans. For example, in July 2021, RSIP Vision, an Israel-based software solution provider, introduced the Articular Cartilage Segmentation Tool. This cutting-edge tool leverages deep learning algorithms to automatically segment cartilage from MRI scans, delivering precise and non-invasive assessments of chondral lesions and cartilage-sparing procedures (such as mosaicplasty, micro-fracture, chondroplasty/osteochondral autograft transfer system, autologous chondrocyte implantation). Physicians utilizing RSIP Vision's module can more accurately evaluate an athlete's cartilage integrity, consequently offering optimal cartilage-sparing treatments. This leads to improved outcomes and shorter recovery times, amplifying the tool's potential to transform patient care within the chondroplasty domain.

In July 2023, Avanos Medical Inc., a prominent US-based company specializing in pain management and chronic care solutions, successfully completed the acquisition of Diros Technology Inc. for a sum totaling $60 million. This strategic acquisition serves to bolster Avanos' standing as a frontrunner in the realm of radiofrequency (RF) technology, expanding its portfolio with a comprehensive range of cutting-edge pain treatment devices. Diros Technology Inc., based in Canada, specializes in crafting radiofrequency devices tailored to address joint disorders such as knee, cervical, and lumbar pain. This acquisition marks a significant step for Avanos, enriching its offerings and solidifying its position within the industry by integrating Diros' expertise and unique devices into its product line.

Major companies operating in the chondroplasty market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Osiris Therapeutics Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Medtronic Public Limited Company, Stryker Corporation, Teva Pharmaceutical Industries Ltd., B. Braun Melsungen AG, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Sigma-Aldrich Corporation, Arthrex Inc., Bio-Rad Laboratories Inc, QIAGEN N.V., CONMED Corporation, Promega Corporation, Organogenesis Holdings Inc., Bioventus LLC, RTI Surgical Holdings Inc., Vericel Corporation, Geistlich Pharma AG, Ocugen Inc., MEDIPOST Co. Ltd., GPC Medical Ltd., Sklar Surgical Instruments, Isto Biologics, Nebula Inc., NuOrtho Surgical Inc., Medical Devices Business Services Inc.

North America was the largest region in the chondroplasty market in 2023. The regions covered in the chondroplasty market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the chondroplasty market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chondroplasty market includes revenues earned by entities by providing services such as microfracture surgery, laser-assisted treatments, and autologous chondrocyte transplantation (ACT). The market value includes the value of related goods sold by the service provider or included within the service offering. The chondroplasty market also includes sales of radiofrequency ablation devices and autologous chondrocyte implants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The main types of chondroplasty include radiofrequency ablation chondroplasty, abrasion chondroplasty, patellar chondroplasty, meniscal repair, tissue removal, and others. Radiofrequency ablation chondroplasty targets minor imperfections in knee cartilage to minimize joint deterioration. Various anatomies, such as knee, shoulder, hip, and others, are addressed using tools such as shavers, radiofrequency devices, and arthroscopes. Chondroplasty procedures are performed in settings such as hospitals, orthopedic clinics, academic research institutions, and others.

The chondroplasty market research report is one of a series of new reports that provides chondroplasty market statistics, including chondroplasty industry global market size, regional shares, competitors with a chondroplasty market share, detailed chondroplasty market segments, market trends and opportunities, and any further data you may need to thrive in the chondroplasty industry. This chondroplasty market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.